Oncological and functional results after robot-assisted radical prostatectomy in high-risk prostate cancer patients.

Autor:	Sánchez-Núñez JE; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México., González-Cuenca E; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México., Fernández-Noyola G; División de Urología, Hospital General Dr. Manuel Gea González., González-Bonilla EA; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México., Doria-Lozano M; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México., Rosas-Nava JE; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México.; Servicio de Urología, Hospital Ángeles del Pedregal.; Centro de Cirugía Robótica, San Ángel Inn Universidad., Corona-Montes VE; Servicio de Urología, Unidad de Uro-Oncología, Hospital General de México Dr. Eduardo Liceaga, Universidad Nacional Autónoma de México.; Servicio de Urología, Hospital Ángeles del Pedregal.; Servicio de Urología, Centro Médico A.B.C. (American British Cowdray) Observatorio. Ciudad de México, México.
Jazyk:	angličtina
Zdroj:	Cirugia y cirujanos [Cir Cir] 2022; Vol. 90 (S1), pp. 1-7.
DOI:	10.24875/CIRU.20001371
Abstrakt:	Background: Pentafecta is currently the standard in the comprehensive evaluation of patients undergoing radical prostatectomy, the objective of this study is the evaluation of oncological and functional outcomes in patients with prostate cancer of high risk undergoing robot-assisted radical prostatectomy. Method: Descriptive, retrospective study of 20 cases with a diagnosis of high-risk prostate cancer. The high-risk group is composed of a prostate-specific antigen equal or greater than 20 ng/mL, Gleason score equal or greater than 8, or clinical stages T2/T3 treated with robotic approach. Results: Biochemical control was achieved from the first six weeks after the surgical event. 75% (n = 15) had negative surgical margins. 100% of the patients (n = 20) presented urinary continence immediately after removal of the urinary catheter. Erectile function was preserved at 3, 6 and 12 months in 100% of the patients who underwent neuropreservation but with use of an PDE inhibitor. (n = 5). Complications were reported in 10% (Clavien-Dindo I-II). Conclusions: Robot-assisted radical prostatectomy in patients with high-risk prostate cancer is considered an appropriate treatment option in selected patients. A different experimental design is needed to define the advantages or disadvantages of this approach, as well as to determine its role and application in clinical practice. (Copyright: © 2022 Permanyer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu